



TRW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO. : 10/729,704  
APPLICANTS : Guenzler-Pukall, et al.  
FILING DATE : 04 December 2003  
GROUP ART UNIT : 1654  
EXAMINER : Roy R. Teller  
DOCKET NO. : FP0602.1 US  
TITLE : TREATMENT OF DIABETES

Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450

**TRANSMITTAL**

The following items accompany this Transmittal:

1. Return Receipt Postcard
2. Response to Examiner's Interview Summary (2pgs, in duplicate)


**Applicants claim small entity status under 37 C.F.R. 1.27.**

The Commissioner is hereby authorized to charge any necessary fees to Deposit Account No. 50-0811, referencing Docket No. FP0602.1 US. This form is enclosed in duplicate.

Please call Applicants' representative at 650.866.7289 with any questions regarding this communication or the above-referenced application.

Respectfully submitted,

Date: 15 January 2008


By:   
James E. Nesbitt, Ph.D.  
Reg. No. 54,575


FibroGen, Inc.  
225 Gateway Boulevard  
South San Francisco, CA 94080  
Main: 650.866.7200  
Direct: 650.866.7289  
Facsimile: 650.866.7292  
[jnesbitt@fibrogen.com](mailto:jnesbitt@fibrogen.com)

**Certificate of mailing or transmission under 37 CFR § 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 15 January 2008.

Name: Michael Moores

Signature: 



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR: SERIAL NO. : 10/729,704  
APPLICANTS : Guenzler-Pukall, et al.  
FILING DATE : 04 December 2003  
GROUP ART UNIT : 1654  
EXAMINER : Roy R. Teller  
DOCKET NO. : FP0602.1 US  
TITLE : TREATMENT OF DIABETES

Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450

**RESPONSE TO EXAMINER'S INTERVIEW SUMMARY**

Sir:

On 11 December 2007, a personal interview between Examiner Roy Teller and applicant's representative James E. Nesbitt, Ph.D., was conducted at the U.S. Patent and Trademark Office to discuss all pending claims in the above-identified application.


Agreement with respect to the claims was not reached. Applicant will amend the claims to include a structural or chemical description of the compounds to be used and a description of the patient population to which the compounds will be administered.

The Commissioner is hereby authorized to charge the total of any fee necessary in this communication to Deposit Account No. 50-0811, referencing Docket No. FP0602.1 US. This response is enclosed in duplicate.

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 15 January 2008.


Name: Michael Moores

Signature: 

Please call Applicants' representative at 650-866-7289 with any questions regarding the present communication or the above-referenced application.

Respectfully submitted,

Date: 15 January 2008

By:   
James E. Nesbitt, Ph.D.  
Reg. No. 54,575

FibroGen, Inc.  
225 Gateway Boulevard  
South San Francisco, CA 94080  
Main: 650.866.7200  
Direct: 650.866.7289  
Facsimile: 650.866.7292  
[jnesbitt@fibrogen.com](mailto:jnesbitt@fibrogen.com)